Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 2Head & Neck 2Sarcoma 1

Conditions

Sarcoma 14Osteosarcoma 9Drug-Related Side Effects and Adverse Reactions 4Gastrointestinal Stromal Tumors 2Uterine Neoplasms 1Neoplasms, Connective and Soft Tissue 1Neoplasm Metastasis 1Liposarcoma 1Head and Neck Neoplasms 1Chordoma 1Chondrosarcoma 1Carcinosarcoma 1Carcinoma 1

Interventions

pembrolizumab 11Gemcitabine 10Doxorubicin 10Cyclophosphamide 9Specimen Handling 8Nivolumab 8Ibandronic Acid 8pazopanib 7Radiosurgery 6Magnetic Resonance Spectroscopy 6Imatinib Mesylate 6Biopsy 6Bevacizumab 6Irinotecan 5regorafenib 4Zoledronic Acid 4Ipilimumab 4Ifosfamide 4Fluorouracil 4Docetaxel 4Cetuximab 4sargramostim 3conatumumab 3cemiplimab 3Sunitinib 3Radiation 3Paclitaxel 3Leucovorin 3Cryosurgery 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × apatinib × Sarcoma × Clear all
NCT02711007 2018-04-23

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

Peking University People's Hospital

Phase 2/3 Completed
37 enrolled
Sarcoma

Neoplasm Metastasis, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡